As US Court Chops Another Symbicort Patent, Will Viatris Make Its Move?
AstraZeneca Tells Generics Bulletin It May Appeal Invalidity Ruling
Viatris has persuaded a US district court that a further patent shielding AstraZeneca’s Symbicort pressurized metered dose inhaler is invalid. The ANDA sponsor, holding the only US FDA approval for a generic version of the blockbuster, has the potential to launch – although a further trial is planned in December.
